MBX Biosciences, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Stock market listings were back on the upswing last quarter, with the eight biotechs floating on Western exchanges raising a total of $1.1bn. In fact, there seems to have been a bit of a rush: three c

BioAge Labs, Inc. switched the development focus for its lead drug candidate, the small molecule apelin receptor (APJ) agonist azelaprag, from age-related muscle loss to prevention of muscle loss in

MBX Biosciences, Inc. , Bicara Therapeutics Inc. and Zenas BioPharma Inc. launched initial public offerings in the US late on 12 September that priced in the middle or at the top of proposed price